EGFR and non-small cell lung carcinoma: In 2004, EGFR mutations were first described among NSCLC [10], with exon 19 deletions and exon 21 L858R point mutations promoting tumorigenesis in approximately 20% of all lung cancers of adenocarcinoma histology [8].